Surgical Treatment of Chronic Pancreatitis: The State of the Art

Marius Kemper, Jakob R. Izbicki, Kai Bachmann

Department of General, Visceral and Thoracic Surgery, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany

Abstract

Chronic pancreatitis is a common disease accompanied with considerable morbidity and mortality. Complications associated with chronic pancreatitis, such as pseudocysts, stenosis of adjacent anatomic structures or pain that cannot be managed conservatively, may be treatable surgically or interventionaly by endoscopy. Surgery is superior to endoscopy in regard to long-term pain management. Duodenum preserving pancreatic resection is the surgical procedure of choice in patients with inflamed changes of the head of the pancreas.

Rezumat

Actualități în tratamentul chirurgical al pancreatitei cronice


Cuvinte cheie: chirurgie, pancreatită cronică, resecție, procedură de drenaj, resecția capului pancreatic cu conservarea duodenului, calitatea vieții
Introduction

Chronic pancreatitis (CP) is a chronic inflammatory process leading to the destruction of and fibrotic changes in the pancreatic parenchyma. Over its progression the disease restricts the pancreas’s exocrine function and in the late stage its endocrine function. In the United States, CP is the most common benign disease requiring hospitalization, emphasizing the socioeconomic significance of the disease (1).

While the precise pathophysiological mechanisms remain unclear, alcohol abuse is seen as an etiological factor (60-70 %). The critical limit is assumed to be the consumption of more than 80 g of alcohol per day over 6-12 years. Smoking promotes the progression of CP (2). An idiopathic genesis must be assumed in 10-30% of cases. Current studies suggest that a gene mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) plays a role in the genesis of idiopathic pancreatitis. A mutation in the CFTR gene leads to a lower tolerance for alcohol (3,4).

Belonging to the rare causes that are present 5% of cases are hyperparathyroidism, malignant obstruction of the pancreatic ductor by an intraductal papillary mucinous neoplasm (IPMN), overuse of analgesics, trauma and genetic predisposition. The causes of hereditary CP include cystic fibrosis and alpha-1-antitrypsin deficiency (5-8). The autoimmune form of CP is associated with elevated levels of serum IgG and autoantibodies, and responds to steroids (9,10).

The prognosis for CP depends on the severity of the disease, frequency of pain episodes, and existing complications. The characteristic complications are pancreatic pseudocysts which pose the risk of infection and rupture, pancreatic duct stricture, and duodenal stenosis. As the disease progresses, pancreatic ascites, malnutrition and chronic pain syndrome may occur. In addition, peptic ulcers, splenic vein and portal vein thromboses, and stenosis of the intrapancreatic bile duct may also occur. CP is a risk factor for pancreatic carcinoma (11).

Clinically, CP presents as an intermittent or persistent band-like pain in the upper abdomen radiating out into the back. For 80-85% of patients pain is the predominant clinical symptom (13,14). Belonging to the pancreatogenic cases of the pain are the inflammatory infiltration of the parenchyma and the nerve sheaths, particularly of the sensitive nerves. Obstructing stones or stenosis can increase the intraductal and intraparenchymatous pressure. Exocrine insufficiency is characterized by steatorrhea and leads to malnutrition over time. Exocrine insufficiency occurs if secretion of the enzymes is reduced by more than 90-95% (15).

Diagnostics

Diagnosis of CP is based on clinical, laboratory and morphological imaging parameters. During the structured anamnesis, questions should be asked explicitly about alcohol consumption, weight loss, frequency and duration of the pain episodes, use of analgesics. Symptoms of endocrine and exocrine insufficiency, and a family history should be also recorded. Suitable as an indicator for quantifying pain and quality of life are the Izbicki pain score and the EORTC Quality of Life questionnaire respectively (16).

The digestive enzymes lipase and amylase can be elevated in the blood. Likewise, in the case of bile duct compression, an increase in
the cholestasis parameters is to be expected. In cases with a suspected autoimmune genesis, the determination of IgG and IgG4 is indicated (17). Where malignancies are suspected, tumor marker Ca-19-9 should be measured. Leukopenia or thrombocytopenia may be present in the case of splenic vein thrombosis.

Performing transabdominal sonography as a basic diagnostic measure is meaningful to clarify differential diagnoses. Among the imaging techniques available, endosonography (EUS) has been established as the most sensitive method. Where there are indistinct signs of pancreatitis (inhomogeneous organ, normally wide pancreatic duct), endosonography with the option of endoscopic-guided fine needle aspiration (EUS-FNP) should be carried out (18). The CT imaging of the abdomen essential for planning surgical intervention enables precise imaging of the pancreatic parenchyma and detection of pancreatic pseudocysts. Another obligatory diagnostic measure prior to an intervention is an MRT including MRCP for detailed visualization of the pancreatic duct. Today, ERCP plays a role in differential diagnostics regarding autoimmune pancreatitis but is otherwise only used for therapy.

**Therapy**

The wide range of conservative, endoscopic, interventional and surgical treatment options requires an extremely high degree of interdisciplinary collaboration. Not only endoscopic therapy, but also surgical therapy for CP requires extensive technical and medical expertise and should therefore only be performed at specialized centers.

Where there are no approaches to address the cause of CP, therapy is limited to managing the symptoms. The components of conservative therapy for uncomplicated cases of CP encompass sufficient analgesics, substitution of pancreatic enzymes, abstention from alcohol and nicotine, and optimized anti-diabetic therapy. Continued alcohol consumption leads to lower survival rates, while with the abstention from alcohol an improvement in the exocrine function is to be expected (19,20).

Complications requiring intervention occur in approximately 30-60% of patients (21). Generally, surgical or endoscopic intervention is indicated as soon as there is a suspicion of malignancy or the presence of therapy-resistant pain, for instance, as a result of stones in the pancreatic duct. Infected pancreatic pseudocysts, bile duct stenosis, gastric outlet obstruction or splenic vein thrombosis are also among the indications for surgery.

Persistent pain requiring analgesics may be treated using endoscopic and surgical procedures. A direct comparison of surgery and endoscopy shows an advantage for the surgical procedure over the longer term follow up (22). A plexus coeliacus blockade leads to a reduction in pain in around 50% of patients. The effect is, however, limited to several weeks. Very little data is available on thoracoscopic splanchnicectomy (23).

Symptomatic pancreatic pseudocysts should be treated regardless of their size. Surgical and endoscopic procedures are available. Surgical procedures more often lead to success, but are associated with a higher rate of lethality compared to endoscopic-guided drainage of pseudocysts into the duodenum or stomach. The success rate for endoscopic transgastric drainage is 65-95%, with a low risk (about 10%) of complications. Asymptomatic pancreatic pseudocysts that are larger than 5 cm and do not regress within six weeks should be treated since the risk of rupture, infection, icterus or bleeding increases (24).

Pancreatic duct stones can lead to obstruction of the pancreatic duct and, as a result, support pancreatic pseudocysts or fistulae, and cause pain episodes. Endoscopic therapy appears to be particularly suitable for treating solitary proximal stenosis, while surgical drainage procedures are superior for treating distal stenosis or in patients with chain of lakes (25).

Cholestasis caused by obstruction of the bile duct in the case of chronic pancreatitis can be treated by endoscopic stenting or surgical procedures. Surgery is particularly superior for treating distal bile duct stenosis with calcifying pancreatitis (25).
Surgical Procedures

Surgical therapy for chronic pancreatitis is effective in treating therapy-resistant pain and local complications.

Long before the function of the pancreas was fully understood, Karl Gassenhauer had already performed a marsupialization of a pancreatic cyst in 1882 (26). In the same year Friedrich Trendelenburg carried out the first distal pancreatectomy. In 1903 Theodor Kocher established a surgical procedure to mobilize the duodenum (27). Based on this, Walther Kausch performed a two-stage pancreaticoduodenectomy in 1909. As a first step, Kausch performed a cholecystojejunostomy and a side-to-side enterostomy. Six weeks later he resected the head of the pancreas with pylorus and partial duodenum. The remaining pancreatic tissue was anastomosed with the duodenum. This evolved to become known as the Whipple procedure still performed today (28). Karl Landsteiner’s discovery of the blood groups and later pioneering of blood transfusion in 1914, along with the discovery of insulin by Frederick Banting in 1921, enabled radical progress in pancreatic surgery (29).

Since the 1960s, numerous surgical strategies, ranging from simple drainage procedure to total pancreatectomy, have been tested in practice as therapy for chronic pancreatitis.

In 1958 Puestow and Gilles first described opening the pancreatic duct by making a longitudinal incision, resecting the pancreatic tail and spleen and then reconstructing the pancreatic outflow via a latero-lateral pancreatico-jejunostomy. The radical extent of the resection results in high morbidity. This technique was modified for this reason by Partington and Rochelle in 1960. Using this technique, which is still performed today, the pancreatic duct is opened in the pancreatic head and body and reconstructed using a Roux loop of jejunum. The tail of the pancreas and the spleen are left intact reducing the risk of endocrine and exocrine pancreatic insufficiency. The resulting decompression leads to lasting analgesia in 50-60% of patients (30,31).

Besides the simple drainage procedures modern resection techniques were established as alternative to the radical Whipple procedure. In 1972 duodenum preserving pancreatic head resections first began to play a role. The technique first described by Beger preserves the duodenum and thus the continuity of the gastroduodenal passage and the bile duct. The pancreas is transected above the portal vein and pancreatic head is subtotal resected. The remaining pancreatic parenchyma is drained via a jejunal loop using two anastomosis (to head and body in the same jejunal loop). Using Roux-en-Y reconstruction it is possible to restore the gastrointestinal passage (Fig. 1). The aim was to retain as much healthy parenchyma as possible while at the same time achieving decompression to control pain. After 5.7 years, 91.3% of the 388 patients included in the follow-up were pain-free (32,33).

In 1985 Frey and Smith supplemented the procedure established by Beger with a longitudinal incision of the pancreatic duct (Partington-Rochelle) which was reconstructed by performing a longitudinal pancreatico-jejunostomy (Frey procedure, Fig. 2). A narrow rim of the pancreatic head is preserved to prevent injury to the bile duct. The procedure has a lower mortality rate (<1%) and less morbidity (9-39%) than the Beger procedure without significant differences regarding pain, endocrine or exocrine functions (34,35). A randomized controlled trial comparing the Frey procedure and the Beger procedure found no differences in terms of quality of life, pain
control, or exocrine or endocrine insufficiencies. The mortality rate of the Beger procedure versus the Frey procedure was comparable with 39% and 34%, respectively (36-39).

In another prospective study, the Frey procedure was compared to the Whipple procedure. The Frey procedure demonstrated itself to be superior in terms of quality of life and pain control in short term follow up and overall survival after 15 years. There were no significant differences regarding exocrine and endocrine insufficiency (40).

Further modifications of duodenum preserving pancreatic head resection include the Berne procedure and the Hamburg procedure which were introduced in 1998 (Fig. 3).

The Berne procedure combines the advantages of the Frey and Beger procedures. In contrast to the Beger procedure, a layer of pancreatic tissue is left on the anterior wall of the portal vein. Within the scope of one study, a mortality rate of 0% and low morbidity of 20% were achieved (41).

The Hamburg procedure was developed in 1998 by Izbicki et al. and is a modification of the Frey procedure to improve the outcome and pain control. Radical excision of the pancreatic head is performed and a longitudinal V-shaped excision is made along the pancreatic duct. This longitudinal incision can be adjusted to match the extent of the pathological changes. Reconstruction is achieved with side-to-side pancreaticojejunostomy (38).

Gold Standard

In more than 85% of patients the findings indicate inflammatory changes to the pancreatic head and an obstruction of the pancreatic duct (42). Resection is indicated in cases of inflammatory pseudotumors of the pancreatic head. The aim is to fully resect the inflamed parenchyma and preserve healthy parenchyma in respect to the residual exocrine and endocrine functions. The duodenum preserving pancreatic head resection is superior to the Kausch-Whipple procedure over short- and medium-term postoperative observational periods because the continuity of both the gastroduodenal passage and the bile duct is maintained. The different variations of duodenum preserving pancreatic head resection appear to be mainly equal to each other in terms of their therapeutic effectiveness (surgeries using the Berger, Frey, Berne, or Hamburg techniques) (16,38,41).

In the case of an obstructed pancreatic duct (> 7 mm) without detection of a pancreatic pseudotumor, as is the case in 10% of patients, it is possible to consider the application of a mere drainage procedure, such as the lateral pancreaticojejunostomy (Partington-Rochelle), whereby poorer long-term outcomes are to be expected when compared to duodenum-preserving pancreatic head resection (38). In case of small duct disease or chain or lakes the V shape excision of the ventral aspect of the pancreas (Izbicki procedure) is recommended. In
the case of bile duct or gastric obstruction, a choledochojunostomy or gastroenterostomy can be considered. Although DEPKR will treat alone probably, Hypersplensimusor recidivating variceal bleeding can be an indication for splenectomy.

**Outlook**

The safety of these procedures has been improved through consistent standardization of the perioperative management and specialization of the surgeons at centers focusing on pancreatic disease. Despite great progress in recent years regarding the management of complications, postoperative morbidity is high.

The optimal point in time for surgery is a controversial topic of discussion. Early surgical intervention may delay the progression of overall pancreatic insufficiency. The current multicenter ESCAPE trial is investigating if early surgical intervention benefits patients in terms of pain relief, endocrine and exocrine function, and quality of life.

Enhanced recovery after surgery (ERAS) protocols, or fast track protocols, aim to optimize pre- and post-operative management by standardizing aspects such as early mobilization, reintroduction of liquids and solids, achieving liquid balance, optimal analgesic therapy, drainage management and choice of antibiotics. Although randomized prospective multicenter trials have not been conducted, retrospective studies show a reduction of hospital stay and a possible reduction of postoperative morbidity (43).

The minimally invasive approach offers numerous benefits in comparison with open surgery, but these procedures can only be performed at highly specialized centers with very highly qualified surgeons. For the first time in 1994 Michael Wagner performed a laparoscopic pylorus preserving pancreatic head resection in a patient with chronic pancreatitis. In a retrospective study it was possible to show that this procedure is feasible and reduces length of hospital stay (44). There are no data on minimally invasive duodenal preserving pancreatic head resections.

The data available on a potential benefit of using robotic approaches for pancreaticoduodenectomy is extremely limited and the technical investments are enormous. Current studies indicate that the 30-day overall complication rate is not significantly different than that for laparoscopic pancreaticoduodenectomy (44). Prospective randomized multicenter trials are needed.

**Conflict of Interest:** none declared.

**References**

31. Partington PF, Rochelle RE. Modified Puestow procedure for retro-
33. Pessaux P, Kianmanesh R, Regimbeau JM, Sastre B, Delcenserie R,
34. Izbicki JR, Bloechle C, Broering DC, Knoefel WT, Kuechler T, Broelts
CE. Extended drainage versus resection in surgery for chronic
pancreatitis: a prospective randomized trial comparing the longitudinal
pancreateicojejunostomy combined with local pancreatic head excision
al. Beger and Frey procedures for treatment of chronic pancreatitis:
2014;219(2):208-16.
36. Izbicki JR, Knoefel WT, Bloechle C, Küchler T, Kühn R, Limmer JC,
et al. The status of duodenum-preserving resection of the head of
the pancreas in therapy of chronic pancreatitis. Zentralbl Chir.
1995;120(4):298-305, German.
37. Izbicki JR, Bloechle C, Knoefel WT, Kuechler T, Binmoeller KF,
Broelts CE. Duodenum-preserving resection of the head of
the pancreas in chronic pancreatitis. A prospective, randomized trial.
38. Strate T, Taherpour Z, Bloechle C, Mann O, Bruhn JP, Schneider C,
et al. Long-term follow-up of a randomized trial comparing the beyer
and frey procedures for patients suffering from chronic
et al. Is the Whipple procedure harmful for long-term outcome in
the treatment of chronic pancreatitis? 15-years follow-up comparing
the outcome after pylorus-preserving pancreatoduodenectomy and
815-20; discussion 820-1.
40. Küniger J, Seiler CM, Sauerland S, Wente MN, Reidel MA, Müller
MW, et al. Duodenum-preserving pancreatic head resection—a
randomized controlled trial comparing the original Beger procedure
41. Traverso LW, Tompkins RK, Ureña PT, Longmire WP Jr. Surgical
treatment of chronic pancreatitis. Twenty-two years’ experience.
42. Barton JG. Enhanced recovery pathways in pancreatic surgery.
43. Lianos GD, Christodoulou DK, Katsanos KH,Katsios C,
Glantzounis GK. Minimally invasive surgical approaches for
2017;48(2):129-134.